Related references
Note: Only part of the references are listed.Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit
Francesco Cucco et al.
LEUKEMIA (2020)
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report
Stuart E. Lacy et al.
BLOOD (2020)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Daisuke Ennishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base
Lindor Qunaj et al.
LEUKEMIA & LYMPHOMA (2018)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Strelka2: fast and accurate calling of germline and somatic variants
Sangtae Kim et al.
NATURE METHODS (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
David M. Kurtz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma
Sarah E. Arthur et al.
NATURE COMMUNICATIONS (2018)
Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
Marcel Nijland et al.
CANCERS (2018)
Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment
Nathan A. Ungerleider et al.
BREAST CANCER RESEARCH (2018)
Haploinsufficiency for NR3C1 Drives Glucocorticoid Resistance By Inactivation the PI3K/AKT/GSK3β/Bim Pathway in Adult Acute Lymphoblastic Leukemia
Xiao Haowen et al.
BLOOD (2018)
Why are there hotspot mutations in the TP53 gene in human cancers?
Evan H. Baugh et al.
CELL DEATH AND DIFFERENTIATION (2018)
Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients
He Cheng et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
TP53 mutation and survival in aggressive B cell lymphoma
Thorsten Zenz et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum
Danielle M. Greenawalt et al.
ONCOTARGET (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma
Anupama Reddy et al.
CELL (2017)
Diffuse large B-cell lymphoma genotyping on the liquid biopsy
Davide Rossi et al.
BLOOD (2017)
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Jonathan C. M. Wan et al.
NATURE REVIEWS CANCER (2017)
Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
Ryan D. Morin et al.
CLINICAL CANCER RESEARCH (2016)
Whole Exome Sequencing of Relapsed/Refractory Patients Expands the Repertoire of Somatic Mutations in Diffuse Large B-Cell Lymphoma
Sylvain Mareschal et al.
GENES CHROMOSOMES & CANCER (2016)
Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma
Mark Roschewski et al.
BLOOD (2016)
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma
Sarit E. Assouline et al.
BLOOD (2016)
Origins, structures, and functions of circulating DNA in oncology
A. R. Thierry et al.
CANCER AND METASTASIS REVIEWS (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones
Thomas Melchardt et al.
ONCOTARGET (2016)
NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy
Chunxiao Xu et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis
Jiyuan Zhang et al.
NATURE MEDICINE (2015)
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development
Ana Ortega-Molina et al.
NATURE MEDICINE (2015)
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer
Muhammed Murtaza et al.
NATURE COMMUNICATIONS (2015)
Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy
Jordina Rovira et al.
ANNALS OF HEMATOLOGY (2015)
Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Matthew J. Maurer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Aaron M. Newman et al.
NATURE MEDICINE (2014)
Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity
J. Xu et al.
CELL DEATH & DISEASE (2014)
Analysis of FOXO1 mutations in diffuse large B-cell lymphoma
Diane L. Trinh et al.
BLOOD (2013)
Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing
K. C. Allen Chan et al.
CLINICAL CHEMISTRY (2013)
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu-Monette et al.
BLOOD (2012)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure
Nathalie A. Johnson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
Pharmacokinetic behavior of rituximab - A study of different schedules of administration for heterogeneous clinical settings
MB Regazzi et al.
THERAPEUTIC DRUG MONITORING (2005)
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
N Mounier et al.
BLOOD (2003)
Share Paper
